Serplulimab: First Approval

Serplulimab (汉斯状 ® ) is an intravenously administered anti-PD-1 antibody being developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours. Anti-PD-1 immunotherapies, such as serplulimab, can stimulate immune responses by relieving PD-1-related immunosuppression. Serplulimab recei...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2022-07, Vol.82 (10), p.1137-1141
1. Verfasser:	Lee, Arnold
Format:	Artikel
Sprache:	eng
Schlagworte:	AdisInsight Report Anemia Antibodies Binding sites Biological products Blood Cancer therapies Cervical cancer Colorectal cancer Gastric cancer Immune response Immunosuppression Immunotherapy Internal Medicine Intestinal obstruction Kidney diseases Lung cancer Medicine Medicine & Public Health Metastases Metastasis Microsatellite instability Microsatellites Patients PD-1 protein Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Solid tumors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Serplulimab (汉斯状 ® ) is an intravenously administered anti-PD-1 antibody being developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours. Anti-PD-1 immunotherapies, such as serplulimab, can stimulate immune responses by relieving PD-1-related immunosuppression. Serplulimab received its first approval on 25 Mar 2022 in China for the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) solid tumours that have failed to respond to previous standard treatments. This article summarizes the milestones in the development of serplulimab leading to this first approval in the treatment of MSI-H solid tumours in adults.
ISSN:	0012-6667 1179-1950
DOI:	10.1007/s40265-022-01740-0